Gene · 338413
Papers2,372
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,372
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Spatiotemporal Regulation of De Novo and Salvage Purine Synthesis during Brain Development. | eNeuro | 2023 | 37770184 | PubTator, text mining | PubMed |
| When You Come to a Fork in the Road, Take It: Wnt Signaling Activates Multiple Pathways through the APC/Axin/GSK-3 Complex. | Cells | 2023 | 37759479 | PubTator, text mining | PubMed |
| Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis. | Eur Respir Rev | 2023 | 37758276 | PubTator, text mining | PubMed |
| Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma. | Cell Death Dis | 2023 | 37749143 | PubTator, text mining | PubMed |
| p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab. | Sci Rep | 2023 | 37749105 | PubTator, text mining | PubMed |
| Abl kinases can function as suppressors of tumor progression and metastasis. | Front Oncol | 2023 | 37746268 | PubTator, text mining | PubMed |
| Two cases of successful sirolimus treatment for patients with activated phosphoinositide 3-kinase δ syndrome 1. | Allergy Asthma Clin Immunol | 2023 | 37742016 | PubTator, text mining | PubMed |
| The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance. | Cancer Res | 2023 | 37725704 | PubTator, text mining | PubMed |
| Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma. | NPJ Precis Oncol | 2023 | 37723227 | PubTator, text mining | PubMed |
| PAK4 inhibition significantly potentiates Gemcitabine activity in PDAC cells via inhibition of Wnt/β-catenin, p-ERK/MAPK and p-AKT/PI3K pathways. | Biochem Biophys Rep | 2023 | 37720313 | PubTator, text mining | PubMed |
| Glutamine deficiency drives transforming growth factor-β signaling activation that gives rise to myofibroblastic carcinoma-associated fibroblasts. | Cancer Sci | 2023 | 37706357 | PubTator, text mining | PubMed |
| Continuous sensing of nutrients and growth factors by the mTORC1-TFEB axis. | Elife | 2023 | 37698461 | PubTator, text mining | PubMed |
| IGF1R Contributes to Cell Proliferation in ALK-Mutated Neuroblastoma with Preference for Activating the PI3K-AKT Signaling Pathway. | Cancers (Basel) | 2023 | 37686528 | PubTator, text mining | PubMed |
| The Impact of ETV6-NTRK3 Oncogenic Gene Fusions on Molecular and Signaling Pathway Alterations. | Cancers (Basel) | 2023 | 37686522 | PubTator, text mining | PubMed |
| Aberrant PI3Kδ splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers. | Front Endocrinol (Lausanne) | 2023 | 37670888 | PubTator, text mining | PubMed |
| Glucocorticoid regulation of the mTORC1 pathway modulates CD4+ T cell responses during infection. | Clin Transl Immunology | 2023 | 37649974 | PubTator, text mining | PubMed |
| TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. | Sci Adv | 2023 | 37647391 | PubTator, text mining | PubMed |
| lncRNA read-through regulates the BX-C insulator Fub-1. | Elife | 2023 | 37643473 | PubTator, text mining | PubMed |
| Knockdown of Porf-2 restores visual function after optic nerve crush injury. | Cell Death Dis | 2023 | 37640747 | PubTator, text mining | PubMed |
| Simultaneous Assessment of mTORC1, JAK/STAT, and NLRP3 Inflammasome Activation Pathways in Patients with Sarcoidosis. | Int J Mol Sci | 2023 | 37628972 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/338413/papers?page=7